<?xml version="1.0" encoding="UTF-8"?>
<p>Although the mode of action of hydroxyurea for HCV, HBV, HSV, and B19V is unknown, viral replications were inhibited by hydroxyurea in 
 <italic>in vitro</italic> studies.
 <sup>
  <xref rid="bibr70-1759720X20947296" ref-type="bibr">70</xref>,
  <xref rid="bibr74-1759720X20947296" ref-type="bibr">74</xref>
  <xref rid="bibr75-1759720X20947296" ref-type="bibr"/>â€“
  <xref rid="bibr76-1759720X20947296" ref-type="bibr">76</xref>
 </sup> Small-scaled clinical trials showed significant reduction of HCV RNA levels and HBV viral loads in chronic HCV and HBV carriers, respectively.
 <sup>
  <xref rid="bibr71-1759720X20947296" ref-type="bibr">71</xref>,
  <xref rid="bibr72-1759720X20947296" ref-type="bibr">72</xref>
 </sup> However, there is a case report of an elderly patient with essential thrombocythemia experiencing reactivation of HBV during treatment with hydroxyurea.
 <sup>
  <xref rid="bibr73-1759720X20947296" ref-type="bibr">73</xref>
 </sup> A retrospective review of children with sickle cell anemia demonstrated decreased requirement of blood transfusion and attenuation of clinical symptoms when using hydroxyurea in patients with B19V infection.
 <sup>
  <xref rid="bibr77-1759720X20947296" ref-type="bibr">77</xref>
 </sup>
</p>
